News

NEWS

The latest news from RHEINCELL

News

RheinCell’s success story

Read about the growth path of RheinCell and what the future might hold in the IHK/Chamber of Commerce and Industry-Magazin

22.07.2021

Read more

News

RheinCell Therapeutics to be acquired by Catalent, Accelerating the Industrialization of iPSC-based Therapies

Catalent Pharma Solutions, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics, cell and gene therapy and consumer health products, has agreed to acquire RHEINCELL Therapeutics.

24.06.2021

Read more

Event

RHEINCELL IS AT ADVANCED THERAPIES 2021 VIRTUAL

Continuously seeking new partnerships and innovative collaborations, Thomas Marx is attending this year's virtual session of Advanced Therapies Congress & Expo. Cutting-edge talks and insightful discussions packed into 3 high-power days will keep Thomas busy. Make sure to join him.

19.05.2021

Read more

Event

RHEINCELL WILL BE AT ISSCR 2021 VIRTUAL

Our colleagues Thomas Marx and Dr. Katja Aschermann will be attending this year's virtual ISSCR meeting. As always, the program is an outstanding list of thought leaders, innovation drivers, and world-class researchers. We hope to see you there.

23.04.2021

Read more

News

RheinCell teams up with RegMedNet to shine a spotlight on iPSCs

RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.

09.04.2021

Read more

Social Media

A NEW PUBLICATION ON THE POTENTIAL OF IPSCS

The April issue of the European Biopharmaceutical Review includes a thought leadership article authored by Thomas Marx and Boris Greber. In it, they explore the potential of induced pluripotent stem cells as meticulously defined starting materials for advanced therapies.

26.03.2021

Read more

News

THOMAS MARX AND BORIS GREBER DISCUSS THE POTENTIAL OF IPSCs

In an informative interview with Michael Adeniya, Portfolio Director of Phacilitate Exchange, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.

09.03.2021

Read more

News

Now you can stay up to date with rheincell news

The advanced therapies market moves quickly with news, updates and breakthroughs every day. As a dynamic and engaged company, we continue to achieve milestones, bring novel ideas, products and services to customers, and expand our partnerships. Follow these developments and activities here on this news page.

16.02.2021

Read more

Event

Rheincell will be at advanced therapies connect 2021

What: A virtual event with strong content agenda where an international network of suppliers, developers and providers of advanced therapies meet to forge collaborations and advance commercial cell-based therapies.

When: January 26 – 27, 2021

23.01.2021

Read more

News

RheinCell Therapeutics achieves milestone GMP certification

We are proud to announce that Rheincell has GMP certification and Manufacturing Authorization to supply clinical-grade iPSCs and thus, make a meaningful contribution to advancing cell therapies.

A special thank you goes out to our team who worked tirelessly to achieve this milestone.

13.01.2021

Read more